PLAINSBORO, N.J. and BAGSVÆRD, Denmark, July 11, 2026 /PRNewswire/ -- Novo Nordisk today unveiled new data from the phase 3 FRONTIER4 extension study evaluating the long-term safety and efficacy of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results